London — Luxury skincare brand Augustinus Bader is forecasting annual sales growth of up to 40% in 2024, as it continues to expand its global presence and product offerings. The company is on track to reach revenue of £170 million ($216 million), up from £122 million ($155 million) in 2023.
Co-founded by biomedical scientist Augustinus Bader and investor Charles Rosier, the brand has gained recognition for its science-driven formulations and cult following. Its flagship creams, known for incorporating the patented TFC8 technology, have become popular among high-profile celebrities and beauty professionals worldwide.
According to company executives, growth is being fueled by increased sales in the United States and Asia, as well as by the launch of new products such as the brand’s first cleanser and hair care line. Augustinus Bader is also investing in research and development to support its long-term goal of applying its regenerative skincare science to broader areas of personal care and wellness.
Despite broader economic uncertainties affecting the luxury and beauty sectors, the brand remains confident in its premium positioning and consumer loyalty. Augustinus Bader products are sold through its own website, major department stores, and online retailers, with the U.S. accounting for about 40% of total sales.
The company is privately held and has not disclosed any plans for public listing or external fundraising in the near term.
